Citadel Advisors
IRMD icon

Citadel Advisors’s iRadimed IRMD Stock Holding History

Citadel Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Buy
+14,700
New +$1.47M ﹤0.01% 6853
2025
Q1 		– Sell
-600
Closed -$33K – 15008
2024
Q4 		$33K Buy
+600
New +$31.6K ﹤0.01% 12784
2024
Q3 		– Sell
-1,600
Closed -$70.3K – 14715
2024
Q2 		$70.3K Sell
1,600
-800
-33% -$34K ﹤0.01% 11371
2024
Q1 		$106K Hold
2,400
– – ﹤0.01% 11282
2023
Q4 		$114K Buy
+2,400
New +$101K ﹤0.01% 10765

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's IRMD Position: Q1 2026 in Review

Citadel Advisors reduced its iRadimed (IRMD) stake by 42% in Q1 2026, selling an estimated $2.33M and leaving 32,504 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5185.

Citadel Advisors first reported a position in IRMD in Q1 2020 and has held it in 17 quarters since. The position peaked at $5.42M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Citadel Advisors held 32,504 shares of iRadimed worth $3.13M as of Q1 2026.
  • Citadel Advisors sold 23,254 iRadimed shares in Q1 2026, an estimated $2.33M.
  • iRadimed made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5185 holding.
  • Citadel Advisors first reported a position in iRadimed in Q1 2020 and has held it in 17 quarters since.
  • Citadel Advisors's iRadimed position peaked at $5.42M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.